|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.930 USD | +12.26% |
|
-17.23% | +17.67% |
| Mar. 30 | Acurx Pharmaceuticals Inc Grants New Patent for Dna Polymerase Iiic Inhibitors | CI |
| Mar. 24 | Top Premarket Gainers | MT |
| Capitalization | 8.37M 7.15M 6.59M 6.22M 11.56M 783M 11.85M 77.18M 30.34M 374M 31.39M 30.73M 1.34B | P/E ratio 2026 * |
-1.34x | P/E ratio 2027 * | -1.58x |
|---|---|---|---|---|---|
| Enterprise value | 8.37M 7.15M 6.59M 6.22M 11.56M 783M 11.85M 77.18M 30.34M 374M 31.39M 30.73M 1.34B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
74.32% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Acurx Pharmaceuticals, Inc.
| 1 day | +12.26% | ||
| 1 week | -17.23% | ||
| Current month | -21.02% | ||
| 1 month | -24.48% | ||
| 3 months | +7.33% | ||
| 6 months | -59.08% | ||
| Current year | +17.67% |
| 1 week | 2.43 |  | 3.13 |
| 1 month | 2.43 | | 7.54 |
| Current year | 1.33 | | 7.54 |
| 1 year | 1.33 | | 21 |
| 3 years | 1.33 | | 176.4 |
| 5 years | 1.33 | | 176.4 |
| 10 years | 1.33 | | 176.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Shawah
DFI | Director of Finance/CFO | 59 | 2017-06-30 |
David Luci
CEO | Chief Executive Officer | 59 | 2017-06-30 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
David Luci
BRD | Director/Board Member | 59 | 2017-06-30 |
Robert de Luccia
CHM | Chairman | 80 | 2017-06-30 |
Carl Sailer
BRD | Director/Board Member | 56 | 2018-10-22 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | -6.34% | 0% | 293,477 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +12.26% | -17.23% | -58.65% | -94.88% | 7.45M | |
| +0.39% | +0.94% | -1.26% | -11.08% | 45.62B | |
| -1.30% | +1.04% | +32.68% | +15.01% | 34.34B | |
| -2.25% | -0.31% | +26.01% | +18.55% | 29.46B | |
| +2.78% | +0.74% | +18.17% | -15.17% | 28.09B | |
| +41.35% | +42.93% | +281.58% | +514.79% | 19.11B | |
| +3.87% | +9.64% | +64.61% | +201.02% | 14.78B | |
| +11.87% | +4.57% | +3,276.98% | +4,354.88% | 14.25B | |
| +1.56% | +1.05% | +68.36% | +157.21% | 14.09B | |
| +1.15% | -2.99% | +36.63% | +3.91% | 13.25B | |
| Average | +7.17% | +2.51% | +374.51% | +514.43% | 21.3B | |
| Weighted average by Cap. | +4.88% | +4.65% | +266.78% | +362.75% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -10.4M -8.88M -8.19M -7.73M -14.37M -974M -14.73M -95.95M -37.72M -465M -39.03M -38.2M -1.66B | -15.22M -13.01M -11.99M -11.32M -21.03M -1.43B -21.56M -140M -55.23M -681M -57.14M -55.93M -2.43B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-04-13 | 2.930 $ | +12.26% | 104,273 |
| 26-04-10 | 2.610 $ | -2.97% | 132,211 |
| 26-04-09 | 2.690 $ | -9.12% | 170,938 |
| 26-04-08 | 2.960 $ | -3.58% | 199,452 |
| 26-04-07 | 3.070 $ | -13.28% | 297,327 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ACXP Stock
Select your edition
All financial news and data tailored to specific country editions
